Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation in vitro independently of PD‐1
Immunology & Cell Biology · 2024-02 · 102 (2) · 117-130
DOI: 10.1111/imcb.12714 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology & Cell Biology, online erschienen am 09.12.2023. Verfasst von Melissa Biemond und 4 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government, Cancer Council Victoria, National Health and Medical Research Council.
Abstract (Originalsprache)
Programmed death receptor 1 (PD‐1) is an inhibitory receptor on T cells shown to restrain T‐cell proliferation. PD‐1 immune checkpoint blockade has emerged as a highly promising approach in cancer treatment. Much of our understanding of the function of PD‐1 is derived from in vitro T‐cell activation assays. Here we set out to further investigate how T cells integrate inhibitory signals such as PD‐1 in vitro using the PD‐1 agonist, PD‐1 ligand 1 (PD‐L1) fusion protein (PD‐L1.Fc), coimmobilized alongside anti‐CD3 agonist monoclonal antibody (mAb) on plates to deliver PD‐1 signals to wild‐type and PD‐1 −/− CD8 + T cells. Surprisingly, we found that the PD‐L1.Fc fusion protein inhibited T‐cell proliferation independently of PD‐1. This PD‐L1.Fc inhibition was observed in the presence and absence of CD28 and interleukin‐2 signaling. Binding of PD‐L1.Fc was restricted to PD‐1–expressing T cells and thus inhibition was not mediated by the interaction of PD‐L1.Fc with CD80 or other yet unknown binding partners. Furthermore, a similar PD‐1–independent reduction of T‐cell proliferation was observed with plate‐bound PD‐L2.Fc. Hence, our results suggest that the coimmobilization of PD‐1 ligand fusion proteins with anti‐CD3 mAb leads to a reduction of T‐cell engagement with plate‐bound anti‐CD3 mAb. This study demonstrates a nonspecific mechanism of T‐cell inhibition when PD‐L1.Fc or PD‐L2.Fc fusion proteins are delivered in a plate‐bound coimmobilization assay and highlights the importance of careful optimization of assay systems and reagents when interpreting their influence on T‐cell proliferation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia.
- Department of Medical Biology, The University of Melbourne, Parkville, VIC, Australia.
ORCID-Profile: Melissa Biemond, Daniel Hd Gray, Philip D Hodgkin, Susanne Heinzel
Förderung
- Australian Government
- Cancer Council Victoria
- National Health and Medical Research Council
- State Government of Victoria
Zitieren
APA
Biemond, M., Vremec, D., Gray, D. H., Hodgkin, P. D., & Heinzel, S. (2024). Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation in vitro independently of PD‐1. Immunology & Cell Biology, 102(2), 117-130. https://doi.org/10.1111/imcb.12714
Vancouver
Biemond M, Vremec D, Gray DH, Hodgkin PD, Heinzel S. Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation in vitro independently of PD‐1. Immunology & Cell Biology. 2024;102(2):117-130. doi:10.1111/imcb.12714
BibTeX
@article{Biemond2024,
author = {Biemond, Melissa and Vremec, David and Gray, Daniel Hd and Hodgkin, Philip D and Heinzel, Susanne},
title = {Programmed death receptor 1 (PD‐1) ligand Fc fusion proteins reduce T‐cell proliferation in vitro independently of PD‐1},
journal = {Immunology & Cell Biology},
year = {2024},
volume = {102},
number = {2},
pages = {117--130},
doi = {10.1111/imcb.12714}
}
EUVIMED